Patent Application Titled "Immunomodulatory RNA" Published Online (USPTO 20230121917).

Předmět:
Zdroj: Women's Health Weekly; 5/9/2023, p1485-1485, 1p
Abstrakt: When the level of unshielded RN7SL1 RNA from the subject is higher than the shielded RN7SL1 RNA, the cancer is aggressive, and the subject is treated with an aggressive cancer therapy. When the level of unshielded RN7SL1 RNA from the subject is higher than the control sample, the subject is resistant to the therapy, and the subject's treatment is altered so as to provide benefit to the subject. When the level of unshielded RN7SL1 RNA from the subject is higher than the control sample, the subject has cancer, and treatment of the cancer in the subject is recommended. When the level of unshielded RN7SL1 RNA from the subject is higher than the level of shielded RN7SL1 RNA, the subject has cancer, and treatment of the cancer in the subject is recommended. [Extracted from the article]
Databáze: Complementary Index